Otsuka Pharmaceutical Company, Limited

Kazuo Sekiguchi

Takumi Sumida

Hideo Tanaka

Takashi Suzuki

Kenji Yoshida

Shigekazu Fujita

Yasuo Yanagihara

Yutaka Kojima

Keisuke Miyajima

Masaaki Motoyama

Kazuhisa Sugiyama

Hideki Takasu

Mitsuhiro Okuno

Naoto Ohi

Takeshi Kodama

Satoshi Yamada

Takashi Nakagawa

Koji Sakai

Makoto Sakamoto

Seiji Akamatsu

Hidekazu Toyobuku

Koichi Yasumura

Keizo Kan

Fujio Tabusa

Tae Fukushima

Yosuke Sato

Kazuhide Ohta

Hisashi Nagamoto

Kunihiko Kiyono

Yutaka Ohbuchi

Masatoshi Iida

Hironori Matsuyama

Toshiyuki Hirose

Yasuo Harada

Takashi Watanabe

Kenji Ohnishi

Norikazu Hashimoto

Kazuhiko Hayashi

Hideo Miyao

Masako Sato

Katsumi Ikezono

Takashi Maeda

Shinya Ohtsuka

The present invention provides a novel compound having an excellent antitumor effect. The compound of the present invention is represented by the following general formula (1) wherein Rand Rare aryl or the like; A is lower alkylene; Ring X is optionally substituted arylene; E is bond or lower alkenylene; Ring Y is optionally substituted heterocycloalkylene containing one or more nitrogen atoms, one of which is attached to the adjacent carbonyl group; G is &#x2014;NH-G-, &#x2014;N(lower alkyl)-G-, &#x2014;NH&#x2014;CH-G-, &#x2014;N(lower alkyl)-CH-G- or &#x2014;CH-G-, [wherein Gbinds to R, G-Ris bond-R, phenylene-G-R, phenylene-G-O&#x2014;R, phenylene-G-NH&#x2014;R, phenylene-G-N(lower alkyl)-Ror quinolinediyl-O&#x2014;R, the phenylene of said phenylene-containing groups being optionally substituted with one or more substituents; G-Ris &#x2014;O-lower alkylene-Ror the like; G-O&#x2014; is lower alkylene-O&#x2014; or the like; Gis lower alkylene; Gis lower alkylene]. 

Di-substituted pyridine derivatives as anticancers

The present invention provides a heterocyclic compound represented by General Formula (1):  

Heterocyclic compound and pharmaceutical composition thereof

An object of the present invention is to provide a STAT3/5 activation inhibitor. The present invention provides a STAT3/5 activation inhibitor containing an aromatic compound represented by the general formula or a salt thereof as an active ingredient: wherein Xrepresents a nitrogen atom or a group &#x2014;CH&#x2550;, Rrepresents a group &#x2014;Z&#x2014;R, in which Z represents a group &#x2014;CO&#x2014;, a group &#x2014;CH(OH)&#x2014; or the like, Rrepresents a 5- to 15-membered monocyclic, dicyclic or tricyclic saturated or unsaturated heterocyclic group having 1 to 4 nitrogen atoms, oxygen atoms or sulfur atoms, Rrepresents a hydrogen atom or a halogen atom, Y represents a group &#x2014;O&#x2014;, a group &#x2014;CO&#x2014;, a group &#x2014;CH(OH)&#x2014; or a lower alkylene group, and A represents a group wherein Rrepresents a hydrogen atom, a lower alkoxy group or the like, p represents 1 or 2, Rrepresents an imidazolyl lower alkyl group or the like.

STAT3/5 activation inhibitor

An object of the present invention is to provide a nucleic acid delivery carrier composition of low toxicity and high safety, the carrier composition, when used to administer a nucleic acid such as an siRNA into an animal-derived cell or organism, being capable of delivering efficiently the nucleic acids into the cells while protecting it from being degraded; and a nucleic acid deliver composition containing the carrier and a nucleic acid. The carrier composition for delivery of a nucleic acid is prepared by mixing (A) a cationic lipid having a steroid skeleton with (B) a tertiary ammonium salt-type cationic lipid. The nucleic acid delivery composition is prepared by mixing the nucleic acid delivery carrier with a nucleic acid.

Carrier composition for nucleic acid transport

The present invention provides a useful and highly safe agent for the treatment of chronic obstructive pulmonary disease, which contains, as the effective ingredient, at least one compound selected from the group consisting of thiazole derivatives and salts thereof represented by the general formula (1), wherein, Ris a phenyl group which may have 1 to 3 lower alkoxy groups as the substituents on the phenyl ring; Ris a pyridyl group which may have 1 to 3 carboxyl groups as the substituents on the pyridine ring.

Agent for curing chronic obstructive pulmonary disease

Growing community of inventors

Osaka, Japan

Kazuo Sekiguchi